1,316 reports of this reaction
8.9% of all PEGVALIASE PQPZ reports
#1 most reported adverse reaction
ARTHRALGIA is the #1 most commonly reported adverse reaction for PEGVALIASE PQPZ, manufactured by BioMarin Pharmaceutical Inc.. There are 1,316 FDA adverse event reports linking PEGVALIASE PQPZ to ARTHRALGIA. This represents approximately 8.9% of all 14,737 adverse event reports for this drug.
Patients taking PEGVALIASE PQPZ who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among PEGVALIASE PQPZ users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for PEGVALIASE PQPZ:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 1,316 FDA reports for PEGVALIASE PQPZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 8.9% of all adverse event reports for PEGVALIASE PQPZ, making it one of the most commonly reported side effect.
If you experience arthralgia while taking PEGVALIASE PQPZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.